RETRACTED ARTICLE: SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness
- 754 Downloads
Gastric cancer is the second leading cause of cancer mortality in the world. Whether the oncogene, amplified on chromosome 3q26, SOX2, a master transcriptional regulator of stemness, operate to drive strong growth phenotype in gastric cancer were unknown.
Materials and methods
The gene expression changes of SOX2 in human gastric cancer tissues compared with non-cancerous tissues was detected using real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohistochemistry, which identified the gene overexpression of SOX2 in gastric cancer. Moreover, we discovered that SOX2 promoted cancer cell proliferation in vitro/vivo and SOX2 expression correlated with elevated AKT phosphorylation in gastric cancer, while the AKT phosphorylation was required for SOX2’s oncogenic effects. Next, our data point to the usefulness of SOX2 overexpression, as a new predictive marker for responsiveness to trastuzumab.
SOX2 is a commonly activated tumor promoter that activate AKT signaling in gastric cancer and a new predictive marker for targeted therapy.
KeywordsSOX2 HER2 Phosphorylation Therapeutic antibody Oncogene
We thank Ms. Min Ding, Dr. Yumin Chen, and Dr. Melissa Cruz, of Institute of Shanghai Springermedia, for the critical review of the manuscript. This work was supported by AfterTumor.com (Grant No. CN1299871A).
Conflict of interest
We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, and there is no professional or other personal interest of any nature or kind in any product, service, and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled “SOX2 Oncogenes Amplified and Operate to Activate AKT Signaling in Gastric Cancer and Predicts Immunotherapy Responsiveness.”
- Kute T et al (2004) Development of Herceptin resistance in breast cancer cells. Cytometry Part A 57(2):86–93Google Scholar
- Levin B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US multi-society task force on colorectal cancer, and the American College of Radiology. CA Cancer J Clin 58(3):130–160PubMedGoogle Scholar
- Scaltriti M et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99(8):628–638Google Scholar
- Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216Google Scholar